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Antiplatelet therapy with aspirin, clopidogrel, and 
dipyridamole versus clopidogrel alone or aspirin and 
dipyridamole in patients with acute cerebral ischaemia 
(TARDIS): a randomised, open-label, phase 3 superiority trial 
Philip M Bath, Lisa J Woodhouse, Jason P Appleton, Maia Beridze, Hanne Christensen, Robert A Dineen, Lelia Duley, Timothy J England, 
Katie Flaherty, Diane Havard, Stan Heptinstall, Marilyn James, Kailash Krishnan, Hugh S Markus, Alan A Montgomery, Stuart J Pocock, 
Marc Randall, Annemarei Ranta, Thompson G Robinson, Polly Scutt, Graham S Venables, Nikola Sprigg, for the TARDIS Investigators* 
Summary 
Background Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for 
preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy 
of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based 
antiplatelet therapy.
Methods We did an international, prospective, randomised, open-label, blinded-endpoint trial in adult participants 
with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset. Participants were assigned in a 1:1 ratio 
using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet therapy (combined 
aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (comprising 
either clopidogrel alone or combined aspirin and dipyridamole). Randomisation was stratified by country and index 
event, and minimised with prognostic baseline factors, medication use, time to randomisation, stroke-related factors, 
and thrombolysis. The ordinal primary outcome was the combined incidence and severity of any recurrent stroke 
(ischaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assessed by central 
telephone follow-up with masking to treatment assignment, and analysed by intention to treat. This trial is registered 
with the ISRCTN registry, number ISRCTN47823388.
Findings 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline anti-
platelet therapy group) were recruited from 106 hospitals in four countries between April 7, 2009, and March 18, 2016. 
The trial was stopped early on the recommendation of the data monitoring committee. The incidence and 
severity of recurrent stroke or TIA did not differ between intensive and guideline therapy (93 [6%] partici -
pants vs 105 [7%]; adjusted common odds ratio [cOR] 0·90, 95% CI 0·67–1·20, p=0·47). By contrast, intensive 
antiplatelet therapy was associated with more, and more severe, bleeding (adjusted cOR 2·54, 95% CI 2·05–3·16, 
p<0·0001).
Interpretation Among patients with recent cerebral ischaemia, intensive antiplatelet therapy did not reduce the 
incidence and severity of recurrent stroke or TIA, but did significantly increase the risk of major bleeding. Triple 
antiplatelet therapy should not be used in routine clinical practice.
Funding National Institutes of Health Research Health Technology Assessment Programme, British Heart Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The risk of recurrence after ischaemic stroke and transient 
ischaemic attack (TIA) is highest immediately after the 
event and declines over the following weeks.1 Although 
aspirin reduces the risk of early recurrence,2,3 dual 
antiplatelet therapy might be more effective, with the 
choice of antiplatelets less important than the use of two 
agents rather than one (at least when considering drugs 
with different modes of action such as aspirin, clopidogrel, 
and dipyridamole).4 Subsequently, the Clopidogrel in 
High-Risk Patients with Acute Nondisabling Cerebro-
vascular Events (CHANCE) trial5,6 found that combined 
aspirin and clopidogrel was superior to aspirin alone in 
preventing recurrence by 90 days in Chinese patients with 
minor ischaemic stroke or TIA when randomly assigned 
within 24 h of onset.
If dual therapy is superior to monotherapy for acute 
secondary prophylaxis, then intensive short-term treat-
ment with three antiplatelet agents might be better still, 
providing the absolute risk of recurrence is high, there is 
a beneficial reduction in recurrence with treat ment, 
and the risk of bleeding on treatment does not become 
excessive. In proof-of-mechanism and proof-of -concept 
studies, triple therapy was more effective than single or 
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dual agents in inhibiting platelet aggregation, platelet–
leucocyte conjugation, and leucocyte activation in vitro7 
and ex vivo in healthy volunteers and participants with 
previous stroke or TIA.8,9 A small trial in participants 
with chronic stroke reported that combined aspirin, 
clopidogrel, and dipyridamole (compared with aspirin 
alone) was feasible to administer for up to 24 months, 
although bleeding was increased with intensive treat-
ment.10 In a case series, long-term administration of triple 
treatment appeared to be useful in participants at very 
high risk of recurrence, defined as recurrence on dual 
antiplatelet therapy.11
The Triple Antiplatelets for Reducing Dependency after 
Ischaemic Stroke (TARDIS) trial compared the safety 
and efficacy of intensive versus guideline-based anti-
platelet therapy in patients with acute non-cardioembolic 
ischaemic stroke or TIA.
Methods
Study design and participants
TARDIS was an international, multicentre, prospective, 
randomised, open-label, blinded-endpoint, superiority trial 
done in 106 sites in four countries (Denmark, Georgia, 
New Zealand, and the UK). Details of the study rationale 
and design, statistical analysis plan, and characteristics 
of the participants have been described elsewhere.12–14 
The protocol is available online. 
Adult patients presenting to hospital in four countries 
were eligible for inclusion if they were at risk of a recurrent 
ischaemic stroke and had either a non-cardioembolic 
ischaemic stroke with limb weakness, dysphasia, or neuro-
imaging-positive hemianopia, or a non-cardioembolic TIA 
with at least 10 min of limb weakness or isolated dysphasia. 
Participants had to be randomly assigned within 48 h of 
symptom onset. Participants who received intra venous 
thrombolysis could be randomly assigned but only 
after 24 h had elapsed after the end of this treatment, 
and providing post-treatment neuro imaging excluded 
secondary cerebral bleeding. 
Key exclusion criteria were age younger than 50 years; 
isolated sensory symptoms, facial weakness, or vertigo 
or dizziness; presumed cardioembolic stroke or TIA; 
parenchymal haemorrhage or other intracranial haem-
orrhage; non-ischaemic cause for symptoms; definite 
need for, or contraindication to, aspirin, clopidogrel, or 
dipyridamole; definite need for full-dose anticoagulation; 
premorbid dependency; or severe hypertension. A full list 
of the study inclusion and exclusion criteria is provided in 
the appendix.
Patients gave written consent, or written proxy consent 
was obtained from a relative or carer if the patient lacked 
capacity. The study was approved by national or local ethics 
committees in each participating country and site and was 
adopted in the UK by the National Institute of Health 
Research Stroke Research Network. National competent 
authorities (or equivalent) gave approvals for this study. 
The trial was overseen by a trial steering committee 
(including five independent members and a patient-public 
representative) and an international advisory committee 
(comprising each national co ordinator). The day-to-day 
conduct of the trial was run by a trial management 
committee based at the Stroke Trials Unit in Nottingham. 
An independent data monitoring committee reviewed 
unblinded data in confidence every 6 months. 
For the study protocol see 
http://tardistrial.org/SA0314%20
TARDIS%20Protocol%20v15.pdf
Research in context
Evidence before this study
We searched PubMed for relevant articles in November, 2012, 
with search terms “antiplatelet therapy”, “aspirin”, 
“dipyridamole”, “clopidogrel”, “ticlopidine”, “prasugrel”, 
“cilostazol”, “triflusal”, “glycoprotein IIb/IIIa receptor 
antagonists”, “stroke”, “cerebral ischemia”, “cerebral 
infarction”, “transient ischemic attack”, and “randomized 
controlled trial”. We also manually searched references from 
original articles and pertinent reviews. Searches were restricted 
to completed trials in human beings with abstracts or full texts 
published. The risk of recurrence after ischaemic stroke and 
transient ischaemic attack (TIA) is highest immediately after 
the event, and is reduced with aspirin. Acute dual antiplatelet 
therapy appears to be more effective according to the CHANCE 
trial. A meta-analysis that included CHANCE found that dual 
antiplatelet therapy significantly reduced the risk of stroke 
recurrence (risk ratio 0·69, 95% CI 0·60–0·80; p<0·001) and 
the composite outcome of stroke, TIA, acute coronary 
syndrome, and all death (0·71, 0·63–0·81; p<0·001) when 
compared with monotherapy, and non-significantly increased 
the risk of major bleeding (1·35, 0·70–2·59, p=0·37). If two 
agents are superior to one, then we hypothesised that 
intensive treatment with three might be better, if the absolute 
risk of recurrence is high, there is a beneficial reduction in 
recurrence with treatment, and the risk of bleeding on 
treatment does not become excessive.
Added value of this study
TARDIS is the only large trial of intensive antiplatelets testing 
the combination of three agents. Intensive antiplatelet 
therapy with three drugs did not reduce the incidence and 
severity of recurrent stroke or TIA, but it did significantly 
increase the risk of major bleeding when compared with 
guideline antiplatelet therapy. Composite endpoints of any 
stroke, fatal haemorrhage, or major haemorrhage, and 
death, stroke, myocardial infarction, fatal haemorrhage, 
or major haemorrhage did not differ between the 
treatment groups.
Implications of all the available evidence 
Triple antiplatelet therapy should not be used in routine 
clinical practice for secondary prevention after ischaemic 
stroke or TIA.
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Randomisation and masking
Demographic and baseline clinical characteristics were 
entered online into a secure web-based database system 
that also provided randomisation. Baseline data were 
checked to confirm the patient’s eligibility and the system 
then assigned the participant to intensive or guide-
line antiplatelet therapy, with allocation in a 1:1 ratio 
(appendix p 9). 
Treatment assignment comprised stratification by 
country and index event (stroke vs TIA) and min-
imisation15 on key prognostic baseline factors (age, sex, 
premorbid function, systolic blood pressure, syndrome 
[cortical vs lacunar and posterior16], previous antiplatelet 
therapy [none or monotherapy vs dual therapy], use of 
gastroprotection, use of low-dose heparin, and time to 
randomisation). Minimisation also included presence 
of crescendo TIAs (more than one TIA in prev-
ious week) and ABCD2 score17 for participants with 
TIA, and National Institutes of Health Stroke Scale 
(NIHSS) and treatment with alteplase for those with 
stroke. Minimisation included a random element in 
5% of patients.
Final follow-up was done centrally at 90 days by 
telephone from the coordinating centre in each country, 
with the assessor masked to treatment allocation. If 
the participant could not be contacted, a questionnaire 
covering the same outcome measures was sent by post.
Procedures
Participants randomly assigned to the intervention group 
received combined aspirin (300 mg load then 50–150 mg 
daily, typically 75 mg, given by oral, nasogastric, or rectal 
routes), clopidogrel (300 mg load then 75 mg daily, given 
by oral or nasogastric routes), and dipyridamole (200 mg 
twice daily modified release, given orally, or 100 mg three 
or four times daily, given by oral or nasogastric route). 
Those randomly assigned to guideline antiplatelet therapy 
received either combined aspirin and dipyridamole, or 
clopidogrel alone (more details are provided in the 
appendix pp 9–10), using the same loading and main-
tenance doses as in the intervention group. Randomly 
assigned antiplatelet drugs were given for 30 days after 
which participants were treated according to local 
guidelines, typically with clopidogrel alone or combined 
aspirin and dipyridamole. Drugs were sourced by each 
participating hospital and could involve any manufacturer 
(including generic sources).
Outcomes
The primary efficacy outcome was the incidence and 
severity of recurrent stroke and TIA during follow-up to 
90 days. Severity was assessed using a six-level ordinal 
scale:13,18 fatal stroke, non-fatal severe stroke (modified 
Rankin Scale [mRS] 4 or 5), moderate stroke (mRS 2 or 3), 
mild stroke (mRS 0 or 1), TIA, and neither stroke nor 
TIA.12,13 The mRS19 is a measure of dependency and scores 
range from zero to six, with a score of zero indicating 
no symptoms, five indicating severe dependency, and 
six indicating death.
Prespecified secondary outcomes at day 90 included 
activities of daily living (Barthel Index [BI]), cognition 
(modified telephone Mini-Mental State Examination 
[t-MMSE], Telephone Interview for Cognition Scale-
modified [TICS-M], and categorical verbal fluency using 
animal naming), health-related quality of life (European 
Quality of Life-5 dimensions-3 level [EQ-5D-3L], from 
which health status utility value [HSUV] was calculated, 
and EQ-Visual Analogue Scale [EQ-VAS]), and mood 
(short Zung Depression Score [ZDS]). At discharge 
from initial hospital admission, duration of hospital 
stay and discharge destination (to institution or home) 
were recorded.
The main safety outcome was haemorrhage on a 
five-level ordinal scale: fatal, major, moderate, minor, 
and none.18 We defined fatal, major, and moderate 
3096 randomly assigned
6 died 6 died
1556 to intensive treatment 1540 to guideline treatment
8 died 8 died
1525 completed day 7 follow-up
 25 missing
 19 patient refused
 6 due to logistical problems
1502 completed day 7 follow-up
 32 missing
 18 patient refused
 14 due to logistical problems
12 died 14 died
1490 completed day 35 follow-up
52 missing
32 patient refused
20 due to logistical problems
1483 completed day 35 follow-up
43 missing
27 patient refused
16 due to logistical problems
1540 with data available analysed for primary 
outcome
16 excluded from primary outcome analysis
1530 with data available analysed for primary 
outcome
10 excluded from primary outcome analysis
1550 completed hospital discharge or death form
6 died in hospital
1529 completed hospital discharge or death form
11 died in hospital
1514 completed day 90 follow-up
16 missing
15 patient refused
1 other reason 
1502 completed day 90 follow-up
10 missing
2 no vital status
3 lost to follow-up
5 patients refused
Figure 1: Study flow 
Screening for eligibility was not collected routinely. 
For the web-based database 
system see https://nottingham.
ac.uk/~nszwww/tardis/
tardistrialdb/tardis_login.php
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haemorrhage according to the International Society on 
Thrombosis and Haemostasis, based on severity, site of 
bleeding, fall in haemoglobin, and need for transfusion.20 
Additional safety outcomes included all-cause and 
cause-specific case fatality, early neurological deterioration 
(defined as an increase from baseline to day 7 of at least 
four points on the NIHSS, or decrease in consciousness 
in the NIHSS consciousness domain), and serious 
adverse events.
To assess the net balance between efficacy and hazard, 
we analysed composite endpoints of any stroke or major 
haemorrhage (including fatal haemorrhage); and death, 
stroke, myocardial infarction, or major haemorrhage.
Participants were seen in clinic at days 7 (on treatment) 
and 35 (end of treatment plus 5–7 days to allow for 
washout) to ascertain whether any outcome or bleeding 
events had taken place (including a full blood count) and 
to determine compliance with treatment. Identification 
of recurrent cerebrovascular events was triangulated 
between investigator reporting at days 7 and 35 and 
through serious adverse events, patient reporting 
at day 90 telephone follow-up, and by the general 
practitioner via a questionnaire posted to them shortly 
after day 90. The primary outcome, haemorrhage, and 
investigator-reported serious adverse events (includ-
ing cause-specific case-fatality) were validated and cate-
gorised by expert adjudicators who were masked to 
treatment assignment. Participants who did not receive 
their assigned treatment or who did not adhere to the 
protocol were still followed up in full at day 90 and 
included in all analyses.
Statistical analyses
The null hypothesis was that intensive antiplatelet 
therapy would not alter recurrence or severity of re-
currence in participants with acute ischaemic stroke or 
TIA. The alternative hypothesis was that stroke and TIA 
recurrence and severity would differ between participants 
randomly assigned to intensive antiplatelet therapy 
versus those assigned to guideline antiplatelet therapy. 
Using an ordinal analysis, we estimated the overall 
sample size at 4100 participants to detect a shift in the 
distribution of the primary outcome with a common 
odds ratio [cOR] of 0·68 (representing the odds of a 
patient on treatment moving to a more severe category of 
outcome compared with a patient on control), two-sided 
type I error of 5%, power of 90%, dropout frequency 
of 2%, treatment crossover of 5%, and adjustment for 
baseline covariates.21 The sample calculation was not 
affected materially by planned interim analyses by the 
data monitoring committee after recruitment and 
follow-up of 40% and 70% of patients; the efficacy 
stopping rule was set at p less than 0·001 for the 
combined outcome of fatal stroke, non-fatal stroke, or 
major bleeding.
We analysed the effect of treatment on the primary 
efficacy outcome as a shift in stroke and its severity, with 
adjustment for the factors used in stratification and 
minimisation at the time of randomisation,15 reported as 
an adjusted cOR with 95% CIs. The odds ratio and 
significance were calculated with ordinal logistic 
regression following a check (using the likelihood ratio 
test) that the assumption of common proportional odds 
was not violated. For sensitivity purposes, the primary 
outcome was also analysed without adjustment, and as a 
binary outcome of fatal or major stroke versus neither. 
The heterogeneity of the treatment effect on the primary 
outcome was assessed in prespecified subgroups by 
adding an interaction term in an unadjusted ordinal 
logistic regression model. Similarly, the effect of 
treatment on the main safety outcome was analysed as a 
shift in bleeding and its severity (fatal, major, moderate, 
minor, or none) with adjustment for the stratification 
Total (n=3096) Intensive 
antiplatelet 
therapy (n=1556)
Guideline 
antiplatelet 
therapy (n=1540)
Age, years* 69·0 (10·1) 69·1 (9·9) 68·9 (10·3)
Sex*
Male 1945 (63%) 982 (63%) 963 (63%)
Female 1151 (37%) 574 (37%) 577 (37%)
Geographical region†
UK 2955 (95%) 1482 (95%) 1473 (96%)
Denmark 51 (2%) 26 (2%) 25 (2%)
Georgia 83 (3%) 45 (3%) 38 (2%)
New Zealand 7 (<1%) 3 (<1%) 4 (<1%)
Medical history
Previous antiplatelet agents
Aspirin 816 (26%) 412 (26%) 404 (26%)
Aspirin and dipyridamole 85 (3%) 43 (3%) 42 (3%)
Clopidogrel 162 (5%) 89 (6%) 73 (5%)
Other 17 (1%) 13 (1%) 4 (<1%)
Previous heparin 7 (<1%) 2 (<1%) 5 (<1%)
Hypertension† 1824 (59%) 930 (60%) 894 (58%)
Hyperlipidaemia 1317/2973 (44%) 655/1496 (44%) 662/1477 (45%) 
Atrial fibrillation‡ 1 (<1%) 0 1 (<1%)
Stroke 348 (11%) 189 (12%) 159 (10%)
Ischaemic heart disease 403 (13%) 196 (13%) 207 (13%)
Peripheral artery disease 70 (2%) 40 (3%) 30 (2%)
Current smoker 784 (26%) 404 (26%) 380 (25%)
Qualifying event†
Ischaemic stroke 2220 (72%) 1121 (72%) 1099 (71%)
TIA 838 (27%) 413 (27%) 425 (28%)
Crescendo§¶ 155/773 (20%) 72/388 (19%) 83/385 (22%)
Patients on dual antiplatelet therapy 
before having their TIA¶ 
36 (4%) 23 (6%) 13 (3%)
Non-ischaemic stroke or TIA|| 38 (1%) 22 (1%) 16 (1%)
Weakness 2789 (90%) 1392 (89%) 1397 (91%)
Sensory loss 1066 (34%) 511 (33%) 555 (36%)
Dysphasia 1007 (33%) 522 (34%) 485 (31%)
Isolated 160 (5%) 88 (6%) 72 (5%)
(Table 1 continues on next page)
Articles
854 www.thelancet.com   Vol 391   March 3, 2018
and minimisation factors. For sensitivity purposes, 
ordinal bleeding was analysed unadjusted and as a 
binary outcome of fatal and major haemorrhage; 
heterogeneity was also assessed. The composite 
outcomes of stroke or major haemorrhage—and death, 
stroke, myocardial infarction, or major haemorrhage—
were compared be tween treatment groups with adjusted 
Cox regression.
We analysed death with Kaplan-Meier and Cox 
regression models. Other outcomes were analysed with 
adjusted multiple linear regression (BI, ZDS, t-MMSE, 
TICS-M, verbal fluency, EQ-5D3L-HSUV, and EQ-VAS). 
Because outcomes such as mRS, EQ-5D3L-HSUV, and BI 
include death (scores of 6, 0, and –5, respectively), and in 
case treatment was associated with asymmetric effects on 
death and other outcome measures (eg, more death but 
less impairment), we added an extreme value for death to 
the other outcome scales (–1 for EQ-VAS, –1 for t-MMSE, 
43 for NIHSS, –1 for TICS-M, –1 for verbal fluency, and 
102·5 for ZDS).22,23
All analyses were done adjusted and unadjusted for 
completeness. The nominal level of significance for all 
analyses, including interaction testing, was p less than 
0·05. No adjustment was made for multiplicity of testing 
for secondary analyses. Data are shown as number (%), 
median (IQR), mean (SD) and either mean difference, 
hazard ratio (HR), or cOR with 95% CIs. All analyses were 
by the intention-to-treat principle for all com parisons, 
including safety analyses. A per-protocol analysis was also 
done on the primary outcome. Statistical analyses were 
done according to the published statistical analysis plan13 
by LJW and KF (with oversight by SJP) using SAS software 
version 9.3.
Role of the funding source
The trial was conceived and designed by the grant 
applicants who wrote the protocol. Study data were 
collected, monitored, and analysed in Nottingham at the 
Stroke Trials Unit. Analysis, interpretation, and report 
writing were done independently of the funders and 
sponsor; no pharmaceutical companies were involved in 
any part of the trial. The corresponding author and two 
statisticians (LJW, KF) had full access to all the data in the 
study; additionally, the corresponding author had final 
responsibility for the decision to submit for publication 
and is the guarantor for the study. The funders had no role 
in study design, data collection, data analysis, data 
interpretation, or writing of the report. The writing 
committee also approved the decision to submit the report 
for publication.
Results
Recruitment commenced on April 7, 2009, and on the 
advice of the independent data monitoring committee 
was halted on March 18, 2016, after enrolment of 
3096 participants (76% of the planned target of 4100; 
figure 1). 28 patients in the intensive treatment group and 
30 in the guideline treatment group were classified as 
inpatients in hospital—participants who were already 
admitted to hospital when they had their qualifying event. 
Most participants were recruited in the UK (2955 [95%]; 
table 1). The mean age was 69·0 years (SD 10·1) and 
1945 (63%) participants were male. Investigations 
after randomisation judged the qualifying event to 
be ischaemic stroke in 2220 (72%) patients, TIA in 
Total (n=3096) Intensive 
antiplatelet 
therapy (n=1556)
Guideline 
antiplatelet 
therapy (n=1540)
(Continued from previous page)
Neglect 331 (11%) 154 (10%) 177 (11%)
Hemianopia 304 (10%) 146 (9%) 158 (10%)
Isolated 16 (1%) 6 (<1%) 10 (1%)
NIHSS (out of 42)* 2·8 (3·6) 2·9 (3·7) 2·7 (3·5)
ABCD2 score (out of 7)* 5·0 (5·0–6·0) 5·0 (5·0–6·0) 5·0 (5·0–6·0)
OCSP classification* 
Number of patients 3094 1556 1538
Total anterior 181 (6%) 86 (6%) 95 (6%)
Partial anterior 1412 (46%) 714 (46%) 698 (45%)
Lacunar 1288 (42%) 646 (42%) 642 (42%)
Posterior 213 (7%) 110 (7%) 103 (7%)
TOAST** 
Cardioembolic‡ 134 (4%) 65 (4%) 69 (4%)
Large vessel 490 (16%) 268 (17%) 222 (15%) 
Small vessel 1224 (40%) 621 (40%) 603 (40%) 
Mixed 22 (1%) 8 (1%) 14 (1%)
Other/undetermined 1182 (39%) 569 (37%) 613 (40%)
Blood pressure
Systolic, mm Hg* 143·5 (18·2) 143·4 (17·8) 143·6 (18·5)
Diastolic, mm Hg 79·5 (11·4) 79·4 (11·3) 79·6 (11·5)
Brain imaging
Number of patients 3092 1555 1537
Normal or no lesion 1550 (50%) 770 (50%) 780 (51%)
Ischaemic stroke 1390 (45%) 702 (45%) 688 (45%)
Non-stroke lesion 6 (<1%) 4 (<1%) 2 (<1%)
No brain scan 146 (5%) 79 (5%) 67 (4%)
Time from onset to randomisation, h* 29·3 (21·8–39·6) 29·3 (21·7–39·7 29·3 (21·9–39·5)
Ischaemic stroke 32·1 (24·7–41·2) 32·2 (24·6–41·7) 32·0 (24·8–41·0)
TIA 24·2 (17·5–29·7) 24·3 (17·5–29·5) 24·2 (17·5–30·0)
Time from onset to randomisation
≤12 h 314 (10%) 147 (9%) 167 (11%)
13–24 h 651 (21%) 342 (22%) 309 (20%)
>24 h 2131 (69%) 1067 (69%) 1064 (69%)
Thrombolysis* 341 (11%) 169 (11%) 172 (11%)
Data are number (%), median (IQR), or mean (SD). TIA=transient ischaemic attack. NIHSS=National Institutes of Health 
Stroke Scale. OCSP=Oxfordshire Community Stroke Project. TOAST=Trial of ORG 10 172 in Acute Stroke Treatment. 
*Minimisation variable. †Stratification variable. ‡Protocol violation. §More than one TIA in previous week. 
¶Participants with TIA only. ||One patient was enrolled with a TIA without previous scan, deteriorated after treatment, 
and on scanning was found to have an intracerebral haemorrhage. **Participants with ischaemia only (n=3052); 
38 patients had their qualifying event reclassified as a non-ischaemic event, resulting in a total of 3058 patients with 
ischaemia. Six of the 3058 patients had missing TOAST data, resulting in 3052 patients with ischaemia only. 
Table 1: Baseline characteristics
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838 (27%) patients, and neither ischaemic stroke nor TIA 
in 38 (1%). The median time from onset to randomisation 
was 29·3 h (IQR 21·8–39·6); 314 (10%) participants were 
recruited within 12 h of onset and 651 (21%) were recruited 
within 13–24 h. In those with an ischaemic stroke, the 
mean NIHSS was 4·0 (SD 3·8) and 336 (16%) of 
2143 patients who were initially randomised received 
thrombolysis. In those with TIA, median ABCD2 score 
was 5·0 (IQR 5·0–6·0) and 155 (20%) of 953 patients 
initially randomised presented with a crescendo TIA 
(defined as more than one TIA over the previous 
week). Among all participants, mean blood pressure 
was 143·5 mm Hg (SD 18·2) systolic and 79·5 mm Hg 
(11·4) diastolic, and the clinical syndrome was cortical in 
1593 (51%) patients, lacunar in 1288 (42%), and posterior 
in 213 (7%).
The advice by the data monitoring committee to 
prematurely terminate recruitment was based on a 
combination of three observations: intensive antiplatelet 
therapy was associated with a significant increase in major 
(including fatal) bleeding; intensive antiplatelet therapy 
was not associated with a significant reduction in the 
primary outcome; and a conditional power analysis 
suggested the trial was highly unlikely to demonstrate a 
significant difference in the primary outcome were it to 
continue. The trial steering committee reviewed the same 
data as well as supplementary analyses on April 12, 2016, 
and noted additionally that there was no difference in the 
net balance of death, stroke, myocardial infarction, and 
major bleeding. They agreed that the trial should stop 
recruitment on the basis of futility.
Final follow-up (at day 90) was completed for 
3016 (97%) participants and vital status was available 
for all but five (<1%; figure 1). Outcomes were determined 
by telephone in 2889 (93%) participants and by post 
in 67 (2%). The primary outcome (further stroke or 
TIA and function at day 90) was determined in 
3070 (99%) participants. Overall, 198 (6%) participants 
had a recurrent stroke or TIA (93 in the intensive therapy 
group vs 105 in the guideline therapy group; table 2), 
comprising 118 strokes (96 ischaemic, 19 haemorrhagic, 
five of unknown type due to absence of neuroimaging, 
one patient with both ischaemic and haemorrhagic 
stroke, and one patient with an ischaemic and an 
unknown type of stroke) and 80 TIAs (of the 88 patients 
who had a TIA, eight also had a recurrent stroke; when 
deriving the primary outcome, the most severe event was 
counted). There was no difference in the incidence and 
severity of stroke or TIA (using the primary efficacy 
outcome of ordered categorical scale comprising fatal 
stroke, stroke with mRS 4 or 5, stroke with mRS 2 or 3, 
stroke with mRS 0 or 1, or TIA) between intensive and 
guideline antiplatelet therapies (adjusted cOR 0·90, 
95% CI 0·67–1·20, p=0·47; table 2, figure 2). When the 
primary outcome was assessed in prespecified subgroups 
(appendix p 26), no significant interactions between the 
primary outcome and treatment were present; in the 
intensive arm there was a tendency for fewer and less 
severe strokes or TIAs in participants presenting with a 
mild stroke and worse outcomes in participants with 
more severe stroke, but this interaction was not significant 
(p=0·070). In a sensitivity analysis, the frequency of 
stroke or TIA by day 90 did not differ between participants 
receiving intensive versus guideline antiplatelet therapy 
(adjusted HR 0·87, 95% CI 0·66–1·16, p=0·34; table 2, 
appendix p 27). However, patients receiving intensive 
treatment were less likely to have a TIA than those 
on guideline therapy (adjusted HR 0·63, 95% CI 
0·41–0·97, p=0·034).
Intensive antiplatelet 
therapy (n=1556)
Guideline antiplatelet 
therapy (n=1540)
Adjusted cOR or 
HR (95% CI)
p value
Primary outcome
Number of patients 1540 1530 ·· ··
Ordinal stroke or TIA 93 (6%) 105 (7%) 0·90 (0·67–1·20) 0·47
Death (mRS 6) 13 (1%) 7 (<1%) 1·92 (0·76–4·84) 0·17
mRS 4–5 11 (1%) 9 (1%) ·· ··
mRS 2–3 22 (1%) 23 (2%) ·· ··
mRS 0–1 15 (1%) 18 (1%) ·· ··
TIA 32 (2%) 48 (3%) ·· ··
No stroke or TIA 1447 (94%) 1425 (93%) ·· ··
Sensitivity analyses
Ordinal, per protocol 65/1089 (6%) 59/1007 (6%) 1·07 (0·74–1·55) 0·72
Stroke or TIA 93/1540 (6%) 105/1530 (7%) 0·87 (0·66–1·16) 0·34
Stroke 61/1540 (4%) 57/1530 (4%) 1·05 (0·73–1·51) 0·79
Ischaemic 46/1540 (3%) 50/1530 (3%) 0·89 (0·59–1·33) 0·56
Haemorrhagic 14/1540 (1%) 5/1530 (<1%) 2·77 (0·99–7·75) 0·052
Unknown 2/1540 (<1%) 3/1530 (<1%) 0·47 (0·05–4·50) 0·51
mRS >2 34/1540 (2%) 28/1530 (2%) 1·19 (0·72–1·97) 0·50
TIA 34/1540 (2%) 54/1530 (4%) 0·63 (0·41–0·97) 0·034
Death 26/1556 (2%) 28/1535 (2%) 0·89 (0·51–1·55) 0·69
Data are number (%), cOR (95% CI) for ordinal stroke or TIA, and for ordinal, per protocol analysis; HR (95% CI) for all 
other analyses. Comparisons by binary logistic regression, ordinal logistic regression, or Cox proportional hazards 
models with adjustment for baseline factors. Stroke or TIA is given by severity; when a patient had more than one 
event over 90 days, the most severe event is used. mRS=modified Rankin Scale. cOR=common odds ratio. HR=hazard 
ratio. TIA=transient ischaemic attack.
Table 2: Efficacy outcomes
Figure 2: Distribution of recurrent stroke and TIA by severity
The primary outcome was incidence and severity of stroke (fatal, mRS 4–5, mRS 2–3, mRS 0–1) and TIA at day 90. 
TIA=transient ischaemic attack. mRS=modified Rankin Scale.
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There was no difference between the treatment groups 
in outcome at day 90 assessed as disability (BI), mood 
(ZDS), cognition (t-MMSE, TICS-M, verbal fluency), or 
quality of life (EQ-5D3L-HSUV, EQ-VAS; appendix p 18). 
Analyses based on unadjusted comparisons did not differ 
qualitatively for either the primary or any of the secondary 
outcomes (data not shown).
The distribution of risk and severity of haemorrhage 
(using the ordinal scale of fatal, major, moderate, mild, 
or no haemorrhage) was shifted to more bleeding and 
bleeding of greater severity in participants randomly 
assigned to intensive antiplatelet therapy (adjusted 
cOR 2·54, 95% CI 2·05–3·16, p<0·0001; table 3, 
appendix p 28). When the distribution of haemorrhage 
and its severity was assessed in prespecified subgroups, a 
statistically significant interaction between haemorrhage 
and the type of comparator was present; intensive 
treatment was associated with more bleeding when 
compared with aspirin and dipyridamole than when 
compared with clopidogrel. An interaction was also seen 
for patients who received thrombolysis; intensive 
antiplatelet therapy was associated with more bleeding in 
those who received thrombolysis than those who did not 
(appendix p 29).
17 (1%) participants receiving guideline antiplatelet 
therapy had severe (fatal or major) haemorrhage by 
day 90, compared with 39 (3%) receiving intensive 
antiplatelet therapy (adjusted HR 2·23, 95% CI 
1·25–3·96, p=0·0063; table 3). The rates of bleeding 
increasingly diverged between the treatment groups up 
to the end of treatment at day 30, but not thereafter 
(appendix pp 19, 30). Combined fatal and major 
intracranial bleeding was increased with intensive 
antiplatelet therapy (adjusted HR 3·84, 95% CI 
1·26–11·63, p=0·018). A non-significant tendency  to 
more fatal or major extracranial bleeding was also seen 
with intensive antiplatelet therapy (adjusted HR 1·89, 
95% CI 0·96–3·71, p=0·064; table 3).
Vital status at end of trial was available for 
3091 participants. There was no evidence of a mortality 
difference between the treatment groups (table 2, 
appendix p 31). Excluding primary outcome and bleeding 
events, the overall occurrence of serious adverse events 
was similar in the two treatment groups (335 [22%] in the 
intensive group vs 327 [21%] in the guideline group; 
adjusted cOR 1·02, 95% CI 0·86–1·22, p=0·80; table 3, 
appendix pp 20, 32); similarly, the occurrence of fatal 
serious adverse events did not differ between the 
treatment groups (13 [1%] in the intensive group 
vs 22 [1%] in the guideline group; adjusted HR 0·52, 
95% CI 0·25–1·05, p=0·070). 
The composite endpoint of any stroke, fatal haemorrhage, 
or major haemorrhage occurred in 87 (6%) participants in 
the intensive group and 69 (5%) participants in the 
guideline group (adjusted HR 1·24, 95% CI 0·90–1·70, 
p=0·19; table 3). Similarly, the composite endpoint of 
death, stroke, myocardial infarction, fatal haemorrhage, or 
major haemorrhage did not differ between the treatment 
groups (102 [7%] in the intensive group vs 98 [6%] in the 
guideline group; adjusted HR 1·02, 95% CI 0·77–1·35, 
p=0·88).
Discussion
In this cohort of patients with acute, non-cardioembolic 
ischaemic stroke or TIA, a regimen of intensive anti-
platelet therapy did not reduce stroke recurrence or its 
severity when compared with guideline antiplatelet 
therapy with either clopidogrel alone or combined 
aspirin and dipyridamole. However, intensive antiplatelet 
therapy was associated with both more, and more severe, 
bleeding. There was no difference in mortality or the 
composite endpoint of stroke or major haemorrhage.
Intensive 
antiplatelet 
therapy (n=1556)
Guideline 
antiplatelet 
therapy (n=1540)
Adjusted cOR or 
HR (95% CI)
p value
Bleeding (safety analysis)
Ordinal bleeding (cOR) 305/1541 (20%) 139/1531 (9%) 2·54 (2·05–3·16) <0·0001
Fatal20 8/1541 (1%) 3/1531 (<1%) 3·48 (0·89–13·63) 0·074
Major 31/1541 (2%) 14/1531 (1%) ·· ··
Moderate 25/1541 (2%) 13/1531 (1%) ·· ··
Mild 241/1541 (16%) 109/1531 (7%) ·· ··
None 1236/1541 (80%) 1392/1531 (91%) ·· ··
Sensitivity analyses
Fatal or major20 39/1540 (3%) 17/1530 (1%) 2·23 (1·25–3·96) 0·0063
Intracranial bleeding 16/1540 (1%) 5/1530 (<1%) 3·14 (1·14–8·61) 0·026
Intracerebral 13/1540 (1%) 4/1530 (<1%) 3·26 (1·05–10·06) 0·040
Subdural or extradural 2/1540 (<1%) 0 ·· NC
Fatal 6/1540 (<1%) 3/1530 (<1%) 2·43 (0·59–10·01) 0·22
Major 9/1540 (1%) 1/1530 (<1%) 8·79 (1·10–69·95) 0·040
Fatal or major 15/1540 (1%) 4/1530 (<1%) 3·84 (1·26–11·63) 0·018
Extracranial bleeding 293/1541 (19%) 135/1531 (9%) 2·37 (1·93–2·91) <0·0001
Gastrointestinal 48/1540 (3%) 34/1530 (2%) 1·39 (0·89–2·16) 0·15
Other 255/1541 (17%) 104/1531 (7%) 2·70 (2·14–3·39) <0·0001
Fatal 2/1540 (<1%) 0 ·· NC
Major 24/1540 (2%) 13/1530 (1%) 1·71 (0·86–3·38) 0·13
Fatal or major 26/1540 (2%) 13/1530 (1%) 1·89 (0·96–3·71) 0·064
Stroke or major bleeding 87/1540 (6%) 69/1530 (5%) 1·24 (0·90–1·70) 0·19
Death, stroke, myocardial 
infarction, or major bleeding
102/1540 (7%) 98/1530 (6%) 1·02 (0·77–1·35) 0·88
Serious adverse events* (cOR) 335/1543 (22%) 327/1531 (21%) 1·02 (0·86–1·22) 0·80
Fatal 13/1543 (1%) 22/1531 (1%) 0·52 (0·25–1·05) 0·070
Severe 54/1543 (4%) 39/1531 (3%) ·· ··
Moderate 167/1543 (11%) 148/1531 (10%) ·· ··
Mild 101/1543 (7%) 118/1531 (8%) ·· ··
None 1208/1543 (78%) 1204/1531 (79%) ·· ··
Data are number (%), cOR (95% CI) for those analyses indicated and HR (95% CI) for the remaining analyses. 
The population of patients in this table was determined by the number of patients with recorded events plus the 
number of patients without events who completed final follow-up. Comparisons by Cox proportional hazards models 
or ordinal logistic regression with adjustment for baseline factors. Haemorrhage is most severe, not first, bleed over 
90 days. No subarachnoid haemorrhages occurred. cOR=common odds ratio. HR=hazard ratio. NC=not calculable. 
*Information on serious adverse events was available for 3074 participants.
Table 3: Safety outcomes by treatment group
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Previous meta-analyses of trials of antiplatelets in 
acute stroke and TIA have suggested that it is the 
number of drugs (ie, two vs one), rather than which 
ones, that is important when determining efficacy, 
at least when considering aspirin, clopidogrel, and 
dipyridamole.4,6 If two antiplatelet agents are better than 
one, then three might be better still, providing that 
bleeding is not overly increased. However, TARDIS 
demonstrated that treatment with three agents does not 
reduce recurrent stroke but does increase haemorrhage. 
Because the primary outcome included haemorrhagic 
stroke, the failure to reduce stroke recurrence and its 
severity overall seems to reflect the combination of 
increased secondary intracranial haem orrhage and a 
tendency to reduced cerebral ischaemic events. Several 
factors appear to explain the results. First, participants 
with a severe stroke (typically cortical strokes) tended to 
do better on guideline therapy whereas intensive 
antiplatelet therapy favoured those with mild stroke. 
Although the risk of recurrence might be greater in 
mild stroke than in severe stroke, the explanation in 
TARDIS is not obvious because stroke severity did not 
seem to influence the effect of treatment on bleeding. 
Second, the type of guideline comparator appeared to 
be important since there was a tendency, albeit non-
significant, for intensive therapy to have beneficial 
effects on the primary outcome in comparison with 
combined aspirin and dipyridamole, but not when 
compared with clopidogrel alone. In parallel, intensive 
antiplatelet therapy was more likely to cause bleeding 
when compared with combined aspirin and dipy-
ridamole than when compared with clopidogrel. 
Nevertheless, these comparisons are indirect because 
most sites did not elect to randomly assign participants 
between the guideline groups.
A confounding factor was the use of thrombolysis, 
which might have increased the difference in bleeding 
between the intensive and guideline antiplatelet therapy 
groups. Trials such as CHANCE and the Acute Stroke 
or Transient Ischaemic Attack Treated with Aspirin or 
Ticagrelor and Patient Outcomes (SOCRATES) study 
excluded patients who received thrombolysis due to 
concerns about haemorrhage, particularly relevant since 
recruitment had to be within 24 h of ictus.5,24 In TARDIS, 
randomly assigned antiplatelet therapy was commenced 
24 h after the completion of any alteplase maintenance 
dose that might have promoted bleeding. A treatment–
thrombolysis interaction was present for bleeding, 
which is surprising because the circulating half-life 
of alteplase is a few minutes (although the tissue 
and biological half-lives might be longer). Further, 
antiplatelet agents were given with a loading dose 
following thrombolysis, as recommended in guidelines, 
and it is possible that this acceleration of antiplatelet 
activity contributed to the risk of bleeding in the 
presence of recent thrombolysis. Nonetheless, this 
finding suggests that bleeding risk is higher following 
intravenous thrombolysis despite an interval of 24 h or 
more between completing alteplase and randomisation 
into the TARDIS study.
To our knowledge, TARDIS is the first trial designed to 
use ordered categorical primary and safety outcomes 
according to fatal event, severe non-fatal event, mild 
non-fatal event, or no event. Empirical analyses of this 
approach with published data from existing trials of 
antiplatelet therapies and other prophylactic interventions 
suggested that it would have more statistical power, or 
the same power for a smaller sample size.18 A key 
secondary aim of TARDIS was to test this methodological 
approach and to compare it with analyses based on 
binary outcomes. Because the primary efficacy analysis 
was non-significant, the relative merits of ordinal versus 
binary analysis could not be adequately assessed for 
stroke. However, ordinal analysis of bleeding gave 
similar, if not more pronounced, results in comparison 
with the outcome of fatal or major bleeding.
The present trial has several strengths, especially gen-
eralisability due to its wide inclusion criteria. In addition 
to motor presentations, patients with acute ischaemic 
stroke included those with severe stroke, dysphasia, or 
neuroimaging-positive hemianopia. Similarly, patients 
with TIA included those with crescendo TIA or who were 
already on dual antiplatelet agents. Hence, groups of 
patients that are typically excluded in stroke prevention 
trials could be enrolled. Inclusion of patients with severe 
stroke meant that those with cortical syndromes, often a 
minority in such trials, could part icipate. The wide time 
window of 48 h meant that patients could be enrolled 
after intravenous thrombolysis. Further more, the trial 
had a large sample size of more than 3000 patients, 
conceal ment of treatment assignment, prospective 
assess ment of multiple outcomes including safety 
measures such as haemorrhage, very high follow-up 
(99% of participants had their primary outcome deter-
mined), care in special ist stroke services, and use of 
locally sourced aspirin, clopidogrel, and dipyridamole 
from a variety of manu facturers (thus increasing the 
external validity of the trial). An additional strength is 
that the results define clearly that although one or two 
agents are safe and effective in acute cerebral ischaemia, 
three agents do not add further efficacy.
Nevertheless, several limitations apply. First, the broad 
population might have included groups more likely to 
either respond (eg, those with minor stroke or TIA, or 
atherosclerotic disease25) or have a major bleed (eg, those 
receiving thrombolysis, or having small vessel disease26), 
which might explain the neutral results; future trials of 
antiplatelets might need to be more specific and focus 
on individuals with atherosclerotic disease. Second, the 
antiplatelet agents were administered in an open-label 
design and participants knew which drugs they were on. 
This aspect could have driven the reporting of known 
adverse events such as headache with dipyridamole 
and bleeding with intensive antiplatelet therapy. In 
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mitigation, outcomes at day 90 were assessed centrally 
and masked to treatment assignment to reduce the 
potential for bias. Third, the comparator group involved 
different antiplatelet agents, a situation reflecting 
changes in national and international guidelines that 
added monotherapy with clopidogrel to the existing 
recommendation of combined aspirin and dipyridamole. 
The PRoFESS mega-trial27 compared these two strategies 
in 20 332 patients with chronic (not acute) ischaemic 
stroke or TIA and showed no differential effect on stroke 
recurrence, although major haemorrhage occurred more 
frequently with combined aspirin and dipyridamole. It 
should be noted that TARDIS did not allow aspirin 
monotherapy (as shown to be effective for ischaemic 
stroke in two mega-trials2,3) as a comparator because it 
was not recommended in UK guidelines for secondary 
prevention in either 2005 or 2010, largely because both 
aspirin with dipyridamole, and clopidogrel alone, had 
previously been shown to be superior to aspirin alone 
in three large trials.28–30 Fourth, randomly assigned 
treatments were given for 30 days, which might have 
been too long in view of the identified haemorrhage risk. 
Importantly, the risk of haemorrhage for intensive and 
guideline antiplatelet therapy diverged from the start of 
randomised treatment and was signifi cantly different 
by 14 days; it is not apparent that a shorter period 
of intensive antiplatelets would have avoided the risk of 
bleeding (appendix pp 13, 19). Last, the trial was stopped 
early following recommendation by the independent 
data monitoring committee and the results could 
represent a false neutral finding related to the 
lower-than-planned statistical power. However, the trial 
recruited more than 70% of its planned target of 
4100 participants and the post-hoc statistical power re-
mained high at 85%. Further, the prespecified effect size 
of 0·68 was almost ruled out (with 95% confidence). As 
such, it is likely that the trial’s main findings are 
correct—ie, that intensive antiplatelet therapy does not 
appear to reduce recurrent cerebral ischaemic events but 
does increase the risk of haemorrhage.
In conclusion, findings from TARDIS show that among 
patients with acute ischaemic stroke or TIA who were 
recruited within 48 h after symptom onset, treatment with 
intensive antiplatelet therapy as compared with guideline 
antiplatelet therapy did not reduce stroke recurrence or its 
severity but did increase haemorrhage and its severity. 
Hence, intensive antiplatelet therapy based on the use of 
three routinely available drugs cannot be recommended 
in acute cerebral ischaemia.
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